GSK plc
corporate_fare Company Profile
GSK plc (NYSE:GSK) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 53 items for GSK at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-14, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for GSK spans 6-K.
Recent high-impact activity:
- Ris-Rez Cuts Death Risk by 54% in Relapsed SCLC: Full Phase III OS Data from GSK
- GSK's Jideytro Shows 94% Response Rate in First-Line ROS1-Positive NSCLC, FDA Filing Planned for 2026
- GSK Advances mRNA Flu Vaccine to Phase III After Positive Phase II Data
- Japan Grants First Global Approval to GSK's Hibsago as a Functional Cure for Chronic Hepatitis B
- FDA Grants Priority Review to GSK's Jemperli for Rectal Cancer, PDUFA Date Set for February 2027
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for GSK, detected from its recent SEC filings · based on capital-structure filings through 2026-09-09.
$6.5B Debt Offering Priced · Proceeds and Pricing
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
GSK files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.